Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Therapeutic options for metastatic melanoma have expanded dramatically over the past decade. Advances in tumor biology, immunotherapy, and adoptive cellular therapy are offering patients more options and requiring oncology advanced practitioners to develop familiarity with increasingly complex treatment modalities and care pathways. Speakers at JADPRO Live 2025 focused on extracutaneous melanoma—particularly mucosal and uveal melanoma—and highlighted novel immune-based therapies, including immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and tumor-infiltrating lymphocyte (TIL) therapy.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Cutaneous Melanoma Detection and Management
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Journal of the Advanced Practitioner in Oncology
- Volume
- 17
- Issue
- 2
- Publication date
- 27 February 2026
- Language
- EN